Lanreotide
Octreotide, sandostatin LAR, lanreotide, vapreotide, somatostatin are names for the same drug. From the pulldown menu below are articles from the Netherlands' experience using Lanreotide gel given subcutaneously every 28 days; there was a (6) six month study with lanreotide showing a percentage reduction in PLD Polycystic Liver Disease. The next article is a case study of two (2) Polycystic Liver Disease patients that had a significant reduction in their liver cyst volume and a diminishing of ascites. Dr. Drenth has another lanreotide clinical trial; all participants will receive 90 mg of lanreotide every 28 days.